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S

keletal muscle, which comprises about 40% of the body mass
of adults, is the main peripheral tissue responsive to insulinstimulated uptake of glucose (1) and is critical in the development
of type 2 diabetes (2). Proper myogenesis is critical for fetal muscle
development (3–5) and postnatal muscle growth and regeneration, which relies heavily on the myogenic differentiation of satellite cells (6–8). In improper myogenesis and muscle regeneration,
damaged muscle fibers are replaced with fibric tissue, leading to
muscle atrophy and aging (9–11).
AMP-activated protein kinase (AMPK) is a heterotrimeric enzyme, composed of ␣, ␤, and ␥ subunits, which plays an important
role in energy metabolism (12–14). In addition to its capacity to
acutely regulate the activity of metabolic enzymes through phosphorylation, AMPK is increasingly recognized for its regulatory
role in gene expression, cell differentiation, and tissue development (15, 16). The role of AMPK in muscle fiber atrophy has been
well defined; a number of studies demonstrated that AMPK promotes muscle protein degradation and autophagy (17) and inhibits protein synthesis (18). To date, however, the role of AMPK in
myogenesis (formation of muscle fibers) has been sparsely studied. Our previous studies showed that low AMPK activity due to
obesity is correlated with attenuated myogenic differentiation
during fetal muscle development (19–21). We further observed
that AMPK promotes myogenin expression and myogenesis
through phosphorylation of histone deacetylase 5 (HDAC5) (22),
suggesting that AMPK has a critical role in myogenesis.
The catalytic ␣ subunit of AMPK has two isoforms, ␣1 and ␣2,
which display differential expression during myogenic cell differentiation (23). Knockout (KO) of either the ␣1 or ␣2 subunit
results in visually normal mice, but KO of both ␣1 and ␣2 subunits is lethal at around embryonic day 9.5 (E9.5) (24), showing
that ␣1 and ␣2 subunits have compensatory roles in regulating
fetal growth and development. We found that AMPK␣1 KO but
not AMPK␣2 KO is associated with reduced muscle mass (22),
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which points to the isoform-specific role of AMPK in myogenesis.
However, there is no direct evidence detailing such an effect. Here
we demonstrate that AMPK␣1 but not AMPK␣2 has a major regulatory role in myogenic differentiation, and AMPK␣1 KO results
in a dramatic reduction in myogenesis.
MATERIALS AND METHODS
Mice. All animals were handled in accordance with protocols approved by
the Animal Use and Care Committees of Washington State University and
the University of Wyoming. Wild-type (WT) C57BL/6 mice, enhanced
green fluorescent protein (EGFP) mice [B6-Tg(CAG-EGFP)131Osb/
LeySopJ, catalog number 006567], red fluorescent (DsRed) mice [B6.CgTg(CAG-DsRed*MST)1Nagy/J, catalog number 006015], and B6;129Gt(ROSA)26Sortm1(cre/ERT)Nat/J mice (catalog number 004847), in which
tamoxifen-inducible Cre recombinase is driven by the endogenous mouse
Gt(ROSA)26Sor promoter, were obtained from the Jackson Laboratory
(Bar Harbor, ME). AMPK␣1⫺/⫺ 129S2/SvPas (AMPK␣1 KO) and
AMPK␣2⫺/⫺ C57BL/6 (AMPK␣2 KO) mice were generated as previously
described (25, 26). Mice with AMPK␣1 floxed, mice with AMPK␣2
floxed, and mice with both AMPK␣1 and AMPK␣2 floxed were generated
as previously described (26) and cross-bred with tamoxifen-inducible Cre
mice to generate AMPK conditional KO mouse strains in which
AMPK␣1, AMPK␣2, or both AMPK␣1 and AMPK␣2 can be deleted in
response to tamoxifen. Red fluorescent (DsRed) mice [B6.Cg-Tg (CAGDsRed*MST)1Nagy/J, catalog number 006015; Jackson Laboratory] were
cross-bred with AMPK␣1 conditional KO mice to generate DsRed-labeled AMPK␣1 conditional KO mice.
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The link between AMP-activated protein kinase (AMPK) and myogenesis remains poorly defined. AMPK has two catalytic ␣
subunits, ␣1 and ␣2. We postulated that AMPK promotes myogenesis in an isoform-specific manner. Primary myoblasts were
prepared from AMPK knockout (KO) mice and AMPK conditional KO mice, and knockout of the ␣1 but not the ␣2 subunit resulted in downregulation of myogenin and reduced myogenesis. Myogenin expression and myogenesis were nearly abolished in
the absence of both AMPK␣1 and AMPK␣2, while enhanced AMPK activity promoted myogenesis and myotube formation. The
AMPK␣1-specific effect on myogenesis was likely due to the dominant expression of ␣1 in myoblasts. These results were confirmed in C2C12 cells. To further evaluate the necessity of the AMPK␣1 subunit for myogenesis in vivo, we prepared both DsRed
AMPK␣1 knockout myoblasts and enhanced green fluorescent protein (EGFP) wild-type myoblasts, which were cotransplanted
into tibialis anterior muscle. A number of green fluorescent muscle fibers were observed, showing the fusion of engrafted wildtype myoblasts with muscle fibers; on the other hand, very few or no red muscle fibers were observed, indicating the absence of
myogenic capacity of AMPK␣1 knockout myoblasts. In summary, these results indicate that AMPK activity promotes myogenesis through a mechanism mediated by AMPK␣1.

Antibodies and chemicals. Antibodies against AMPK␣ (catalog number 2532), phospho-AMPK␣ at Thr172 (number 2535), acetyl coenzyme
A carboxylase (ACC) (catalog number 3662), phospho-ACC at Ser79
(catalog number 3661), tag (catalog number 2368), mouse IgG (catalog
number 7076) and ␤-tubulin (catalog number 2146 and goat anti-mouse
antibody–Alexa Fluor 555 (catalog number 4409), goat anti-rat antibody–
Alexa Fluor 488 (catalog number 4416), and goat anti-rabbit antibody–
Alexa Fluor 555 (catalog number 4413) were purchased from Cell Signaling (Danvers, MA). Antimyogenin (F5D), anti-embryonic myosin heavy
chain (anti-EMH) (F1.652), and anti-myosin heavy chain (anti-MHC)
(MF20) mouse monoclonal antibodies were obtained from the Developmental Studies Hybridoma Bank (Iowa City, IA). Rabbit antidesmin antibody (ab15200) and chick anti-GFP antibody (ab13970) were purchased
from Abcam (Cambridge, MA). Rat antilaminin antibody (4H8-2) was
purchased from Enzo (Farmingdale, NY). Rabbit anti-DsRed antibody
(catalog number 632496) was purchased from Clontech (Mountain View,
CA). Goat anti-chick antibody–Alexa Fluor 488 (catalog number A11039)
was purchased from Life Technologies (Grand Island, NY). IRDye
800CW– goat anti-rabbit secondary antibody and IRDye 680 – goat antimouse secondary antibody were purchased from Li-Cor Biosciences (Lincoln, NE). Puromycin, compound C, cardiotoxin (CTX), and 4-hydroxytamoxifen (TM) were purchased from Sigma (St. Louis, MO).
MC1568 was purchased from Selleck (Houston, TX). AICAR (5-aminoimidazole-4-carboxamide 1-beta-D-ribonucleoside) (5 mM) was purchased from Toronto Research Chemicals (Toronto, Canada). Lipofectamine was purchased from Invitrogen (Carlsbad, CA). Basic fibroblast
growth factor (FGF2) (catalog number 233-FB-025) was purchased from
R&D Systems (Minneapolis, MN).
Cell culture. Myogenic C2C12 cells were grown at 37°C with 5% CO2
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and a 1% antibiotic mixture. Primary myoblasts were extracted from neonatal mice according to a procedure described previously, with modifications (27). Briefly, muscle from hind
limbs was minced and digested in DMEM with collagenase D and dispase
II (Roche Diagnostics GmbH, Mannheim, Germany) at 37°C for about 30
min. The slurry was then passed through a 100-m cell strainer. Cells were
collected by centrifugation at 350 ⫻ g for 5 min. The cell pellet was then
resuspended in F-10 medium with 20% FBS, a 1% antibiotic mixture, and
5 ng/ml FGF2. Primary myoblasts were seeded onto collagen-coated
plates and enriched by preplating. The purity of enriched primary myoblasts was checked by fluorescence-activated cell sorter (FACS) analysis
using an antidesmin antibody. When cells reached 80% confluence, culture medium was switched to DMEM supplemented with 2% horse serum
and a 1% antibiotic mixture to induce myogenic differentiation. AMPK
conditional KO cells were supplemented with 1 M 4-hydroxytamoxifen
for 48 h to KO the AMPK␣ subunit.
Immunoblotting analyses. Immunoblotting analysis was performed
as previously described, using an Odyssey infrared imaging system (LiCor Biosciences, Lincoln, NE) (28). Band density was normalized to ␤-tubulin content.
Real-time quantitative PCR. Total RNA was extracted by using
TRIzol (Sigma, St. Louis, MO) followed by DNase (NEB, Ipswich, MA)
treatment, and cDNA was synthesized by using a reverse transcription kit
(Bio-Rad, Hercules, CA). Real-time PCR (RT-PCR) was carried out by
using a CFX RT-PCR detection system (Bio-Rad) with a SYBR green
RT-PCR kit from Bio-Rad (Hercules, CA). The following cycle parameters were used: 34 three-step cycles of 95°C for 20 s, 55°C for 20 s, and 72°C
for 20 s. Primer sequences (with their respective PCR fragment lengths in
parentheses) were as follows: forward primer 5=-GAGATCCTGCGCAG
CGCCAT-3= and reverse primer 5=-CCCCGCCTCTGTAGCGGAGA-3=
for myogenin (97 bp), forward primer 5=-TGCTGTCCCTGTATGCCTC
T-3= and reverse primer 5=-TGTAGCCACGCTCGGTCA-3= for 18S
rRNA (110 bp), forward primer 5=-CTCAGTTCCTGGAGAAAGATG
G-3= and reverse primer 5=-CTGCCGGTTGAGTATCTTCAC-3= for
AMPK␣1 (174 bp), forward primer 5=-CATGGCTGAGAAGCAGAAGC
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AC-3= and reverse primer 5=-CTTAACTGCCACTTTATGGCCTG-3= for
AMPK␣2 (136 bp), forward primer 5=-GTGGACCCCTACAGCTACAA
ACC-3= and reverse primer 5=-TGGAAGAAAGGCGCTGAAGAC-3= for
MRF4 (181 bp), forward primer 5=-TCTGGAGCCCTCCTGGCACC-3=
and reverse primer 5=-CGGGAAGGGGGAGAGTGGGG-3= for MyoD
(100 bp), and forward primer 5=-AAACTCCGGGAGCTCCGCCT-3= and
reverse primer 5=-GGCAGCCGTCCGTCATGTCC-3= for Myf5 (125 bp).
After amplification, a melting curve (0.01°C/s) was used to confirm product purity, and agarose gel electrophoresis was performed to confirm that
only a single product of the right size was amplified. Relative mRNA
content was normalized to 18S rRNA content.
Transfection. Plasmid transfection of C2C12 cells was performed by
using Lipofectamine according to the manufacturer’s instructions (Life
Technologies, Grand Island, NY). Briefly, 12 h before transfection, cells
were switched to medium without antibiotics. Transfections were carried
out when cells reached 80% confluence, using a 1:3 ratio of DNA (g) to
Lipofectamine (l); medium was switched to DMEM containing 10%
FBS and 1% antibiotics 12 h following transfection.
For short hairpin RNA (shRNA) interference, AMPK␣1 shRNA,
AMPK␣2 shRNA, and control shRNA (Santa Cruz Biotech, Santa Cruz,
CA) were delivered into cells, and transfected cells were selected with
puromycin (2 g/ml).
Induction of muscle regeneration, fluorescent myogenic cell transplantation, and in vivo tracing. Myogenic cells were separated from
neonatal mice. DsRed AMPK␣1 conditional KO myoblasts were
treated with tamoxifen for 48 h to induce AMPK␣1 KO. WT EGFP
myoblasts were treated simultaneously. Because in these mice, both
DsRed and EGFP are under the control of a chicken ␤-actin promoter
and the overall transgenic constructs between these two fluorescent
mice are very similar and are in the same C57BL/6 background, DsRed
and EGFP transgenesis does not affect the myogenic capacity of myogenic cells. Three-month-old C57BL/6 mice were used as the recipient
mice. Briefly, 1 day before cell transplantation, recipient mice were
anesthetized by administration of a mixture of ketamine (100 mg/kg of
body weight) and xylazine (10 mg/kg) (intraperitoneally [i.p.]). Next,
100 l of 10 M cardiotoxin was injected into the tibialis anterior (TA)
muscle to induce muscle regeneration (9). After 1 day, mice were ready
for cell transplantation; 6 ⫻ 104 cells (3 ⫻ 104 WT green cells and 3 ⫻
104 AMPK␣1 KO red fluorescent cells, which were mixed before injection) in 50 l phosphate-buffered saline (PBS) were slowly injected
into the TA muscle by using a 29-gauge needle (9, 29). Fourteen days
after transplantation, mice were sacrificed, and TA muscle was collected, fixed in 4% paraformaldehyde, and frozen in isopentane cooled
in liquid nitrogen. Frozen tissue was sectioned (5 to 10 m thick).
Sections were blocked in 5% goat serum in Tris-buffered saline (TBS)
containing 0.3% Triton X-100 and stained with chick anti-GFP antibody (1:1,000), rabbit anti-DsRed antibody (1:500), and the corresponding fluorescent secondary antibodies. Green fluorescent muscle
fibers and red fluorescent muscle fibers on sections at 100-m intervals were counted.
Immunocytochemical staining. Cells grown on coverslips or multiple-well plates were fixed in 4% paraformaldehyde for 10 min, permeabilized with cold methanol for 5 min, quenched with 0.1% sodium borohydride for 5 min, and incubated with anti-MHC or mouse IgG (1:100) at
4°C overnight. Fluorescent secondary antibody (1:1,000) was then added,
and stained cells were incubated at room temperature for 1 h. Fluorescence was examined by using a Leica inverted microscope (28). Fusion
indexes of differentiating myoblasts were calculated by dividing the number of nuclei in MHC-positive myotubes by the total number of nuclei.
Statistics. For all studies, at least 3 independent experiments were
conducted. All data are expressed as means ⫾ standard errors of the mean
(SEM). Data were analyzed by using the general linear model (GLM) of
SAS (SAS Institute Inc., Cary, NC), and Tukey’s Studentized range test
was used to determine the significance of differences among means. A P
value of ⬍0.05 was considered significant.
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6 h, and AMPK, ACC, phospho-AMPK (p-AMPK), and phospho-ACC (p-ACC) protein contents were analyzed by immunoblotting. (B to F) Endogenous
AMPK␣1 and AMPK␣2 were knocked down by shRNA in C2C12 cells. (B) AMPK␣1 and AMPK␣2 mRNA contents were analyzed by RT-PCR. (C) ACC and
p-ACC protein contents were analyzed by immunoblotting. (D) Myogenin mRNA content (2 days after induction of myogenesis). (E) Myogenin and MHC
protein contents (3 days and 6 days after induction of myogenesis, respectively). (F) Immunocytochemical staining of AMPK␣1 and AMPK␣2 knockdown
C2C12 cells using an anti-MHC antibody 6 days after induction of myogenesis. Data shown are means ⫾ SEM (n ⱖ 3). ␣1, AMPK␣1; ␣2, AMPK␣2; DAPI,
4=,6-diamidino-2-phenylindole. ⴱ, P ⬍ 0.05 versus the control; ⴱⴱ, P ⬍ 0.01 versus the control.

RESULTS

AMPK␣1 inhibition attenuates myogenesis in C2C12 cells. The
reduction of AMPK activity has significant physiological relevance, because obesity and its associated chronic low-grade inflammation reduce AMPK activity via elevating tumor necrosis
factor alpha (TNF-␣) levels (30, 31). To test if TNF-␣ inhibits
AMPK in myoblasts, we treated C2C12 cells with TNF-␣ (10 ng/
ml). TNF-␣ treatment reduced AMPK phosphorylation at
Thr172, a marker of AMPK activity. We further analyzed phosphorylation of Ser79 in acetyl coenzyme A carboxylase (ACC), a
site exclusively phosphorylated by AMPK, and found that, indeed,
ACC Ser79 phosphorylation was reduced in cells treated with
TNF-␣ (Fig. 1A).
To assess the relationship between decreased AMPK activity
and myogenesis, we stably transfected C2C12 cells with plasmids expressing either AMPK␣1 or AMPK␣2 short hairpin
RNA (shRNA). We found that about 40% of endogenous
AMPK␣1 and AMPK␣2 were knocked down by their respective
shRNAs (Fig. 1B); the activity of both subunits was also decreased, as indicated by decreased phosphorylation of ACC
(Fig. 1C).
We further observed that AMPK␣1 but not AMPK␣2 knockdown was associated with decreased myogenin mRNA content
(Fig. 1D). Consistently, myogenin protein content was decreased
when AMPK␣1 was knocked down (Fig. 1E). As expected, both
myosin heavy chain (MHC) protein content and the number of
mature myotubes were decreased only when AMPK␣1 was
knocked down (Fig. 1E and F).
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AMPK␣1 activity is necessary for myogenesis in primary
myoblasts in vitro. Because only about a 40% knockdown of
AMPK␣ subunits was achieved by shRNA, we assessed myogenin
mRNA expression in differentiating primary myoblasts from neonatal WT, AMPK␣1 KO, and AMPK␣2 KO mice. Desmin staining
showed that the primary myogenic cells which we prepared had
very high purity, eliminating the possibility that the detected difference was due to an impurity of primary myogenic cells (Fig.
2A). We observed that myogenin mRNA expression was profoundly reduced in AMPK␣1 KO myoblasts but not in AMPK␣2
KO myoblasts (Fig. 2B). Consistently, AMPK␣1 KO was associated with a dramatic decrease in myogenin protein content (Fig.
2C), whereas AMPK␣2 KO showed no significant difference (Fig.
2D). We also found that AMPK␣1 KO but not AMPK␣2 KO was
associated with a decreased MHC level (Fig. 2C and D). In addition, myotube formation in AMPK␣1 KO myoblasts but not in
AMPK␣2 KO myoblasts was reduced (Fig. 2E and F). Two days
after induction of myogenesis, the mRNA levels of additional
myogenic regulatory factors (Myf5, MyoD, and MRF4) in WT
myoblasts and AMPK␣1 KO myoblasts were also tested. While no
difference was seen in MyoD and MRF4 mRNA levels, the Myf5
mRNA level was higher in AMPK␣1 KO myoblasts than in WT
myoblasts, which suggests a specific regulatory effect of AMPK on
myogenin expression (Fig. 2G). Myf5 is known to express prior to
myogenin and is able to induce myogenin expression (32, 33), and
thus, it is possible that the elevated level of Myf5 in AMPK␣1 KO
myoblasts was due to compensatory effects. Another possibility is
that the halted fusion of AMPK␣1 KO myoblasts into myotubes
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FIG 1 AMP-activated protein kinase knockdown reduces myogenesis in C2C12 cells. (A) C2C12 cells were treated with TNF-␣ (10 ng/ml) or vehicle (PBS) for

Fu et al.

rendered more abundant myoblasts which express Myf5, resulting
in higher Myf5 expression levels in AMPK␣1 KO than in WT
differentiating myoblasts.
We reasoned that if AMPK was necessary for myogenesis, then
knocking out both AMPK␣1 and -␣2 should prevent the formation of myotubes. Because the double knockout (DK) of AMPK␣1
and -␣2 subunits is embryonically lethal, we prepared primary
myoblasts from tamoxifen-inducible AMPK␣1 and AMPK␣2
conditional KO mice (AMPK DK mice). AMPK DK primary myoblasts were treated with 1 M 4-hydroxytamoxifen (TM) for 2
days to achieve complete depletion of AMPK␣ protein (Fig. 3A).
As expected, the absence of AMPK activity was associated with
dramatic reductions in myogenin mRNA expression levels (Fig.
3B), myogenin protein content (Fig. 3C), MHC levels (Fig. 3C),
and myotube formation (Fig. 3D), clearly illustrating the critical
role of AMPK in myogenesis.
Expression of AMPK␣1 and AMPK␣2 subunits during myogenesis. To dissect the effects of isoform-specific depletion of
AMPK␣1 and -␣2 subunits on myogenesis, we tested whether the
difference was caused by the differential expression of AMPK␣1
and AMPK␣2 in myoblasts. While the AMPK␣1 mRNA level remained constant during 6 days of myogenic differentiation in
C2C12 cells, the AMPK␣2 mRNA level increased about 4-fold
(Fig. 4A). In primary myoblasts, 2 days after myogenic induction,
the AMPK␣1 mRNA level decreased approximately 30%, while
the AMPK␣2 mRNA level increased 4-fold (Fig. 4B). The mRNA
levels of AMPK␣1 and AMPK␣2 in the hind-limb muscles from
neonatal (2 days old, with highly active myogenic differentiation)
and adult (2 months old, with mature muscle fibers and only
limited myogenesis) WT mice were further compared. The
AMPK␣1 mRNA level was about 9-fold higher in neonatal mice
than in adult mice, whereas the AMPK␣2 mRNA level was about
50% lower in neonatal mice than in adult mice (Fig. 4C). These
data show that the AMPK␣1 level decreases gradually during
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myogenic differentiation, while the AMPK␣2 level increases during this process, indicating the importance of AMPK␣1 in early
myogenesis.
To further clarify AMPK␣ subunit expression, total AMPK␣
protein levels (␣1 and ␣2 subunits were included because the antibody does not differentiate these two subunits) and activity,
based on the phosphorylation of AMPK␣ Thr172, were measured
in differentiating WT, AMPK␣1 KO, and AMPK␣2 KO myoblasts. Both AMPK␣ protein levels and activity were lower in
AMPK␣1 KO myoblasts than in WT myoblasts 3 days after induction of myogenesis, despite the finding that the AMPK␣2 mRNA
level increased dramatically 2 days after induction of myogenesis,
which suggests an extremely low expression level of AMPK␣2 in
undifferentiated and differentiating myoblasts (Fig. 4B and D).
There were no differences in AMPK␣ protein levels and activity
between WT myoblasts and AMPK␣2 KO myoblasts (Fig. 4D),
further showing that AMPK␣2 expression is minor in myoblasts.
AMPK␣ protein levels and activities in the hind-limb muscle
from neonatal and adult WT and AMPK␣ KO mice were further
measured. Both AMPK␣ protein levels and activities were lower in
neonatal AMPK␣1 KO mice than in neonatal WT mice, showing
that AMPK␣1 is the dominant form in neonatal muscle (Fig. 4E);
however, the difference was reduced in adult mice (Fig. 4F). There
was no significant difference in AMPK␣ protein levels and activities between neonatal AMPK␣2 KO mice and neonatal WT mice
(Fig. 4E), whereas the difference was significant in adult mice,
which indicates that the ␣2 subunit was the dominant form in
adult mice (Fig. 4F). These data suggest that AMPK␣1 is abundantly expressed in myoblasts, while AMPK␣2 is preferentially
expressed in mature muscle fibers.
During muscle regeneration, satellite cells proliferate and then
fuse to damaged muscle fibers or form new muscle fibers to replace damaged ones. To test the levels of AMPK␣1 and AMPK␣2
in regenerating muscle, we induced muscle regeneration in TA
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FIG 2 AMP-activated protein kinase activity is necessary for myogenesis in primary myoblasts. WT, AMPK␣1 KO, and AMPK␣2 KO primary myoblasts were
prepared, purified, and induced for myogenesis. (A) The purity of enriched myoblasts was evaluated by FACS analysis. The blue line shows myoblasts stained with
rabbit antidesmin primary and Alexa Fluor 488-conjugated secondary antibodies. The red line shows control staining without primary antibody. (B) Myogenin
mRNA content (2 days after induction of myogenesis). (C and D) Myogenin and MHC protein contents (3 days and 4 days after induction of myogenesis,
respectively). (E and F) Immunocytochemical staining using an anti-MHC antibody and fusion index 4 days after induction of myogenesis. (G) Myf5, MyoD, and
MRF4 mRNA contents (2 days after induction of myogenesis). Data shown are means ⫾ SEM (n ⱖ 3). ␣1, AMPK␣1; ␣2, AMPK␣2. ⴱⴱ, P ⬍ 0.01 versus the WT;
ⴱⴱⴱ, P ⬍ 0.0001 versus the WT.

AMPK Enhances Myogenin Expression and Myogenesis

muscle by cardiotoxin (CTX) injection. AMPK␣1 and AMPK␣2
mRNA levels at different days post-CTX injection were tested.
Both AMPK␣1 and AMPK␣2 mRNA levels decreased at 1 day
post-CTX injection, possibly due to the severe harmful effect of
CTX on cell physiology. Surprisingly, a ⬎30-fold increase in the
AMPK␣1 mRNA level was observed in muscle at 3 days post-CTX
injection, which correlates with the expression of embryonic myosin heavy chain (EMH), a marker of muscle regeneration (9).
However, AMPK␣2 levels only returned to the level prior to damage at 3 days post-CTX injection (Fig. 4G and H). The increased
AMPK␣1 mRNA level in regenerating muscle strongly indicates
its importance in myogenesis.
Both AMPK␣1 and AMPK␣2 are able to promote myogenesis. The question that remains is whether both AMPK␣1 and
AMPK␣2 subunits are able to promote myogenin expression and,
thus, myogenesis. To address this question, we treated C2C12 cells
and primary myoblasts with 5-aminoimidazole-4-carboxamide
1-beta-D-ribonucleoside (AICAR) and an AMPK inhibitor, compound C. Because high levels of AMPK activity are known to inhibit universal protein synthesis (by attenuating mTOR signaling
and inhibiting myogenin and MHC expression), we sought to
minimize such possible side effects by using a low concentration
of AICAR (0.125 mM) to induce a low level of activation; similarly, a low concentration of compound C (1 M) was used.
AMPK activity was assessed by measuring phosphorylation levels
of AMPK␣ Thr172 and ACC Ser79 following AICAR and compound C treatments in C2C12 cells (Fig. 5A). AMPK activation by
AICAR resulted in an increase in the myogenin mRNA level and
protein content and an increase in the MHC protein content in
C2C12 cells (Fig. 5B and C). In agreement with this finding, myo-

November 2013 Volume 33 Number 22

tube formation was enhanced in AICAR-treated C2C12 cells,
which indicates that a low level of AMPK activation promotes
myogenesis (Fig. 5D). A reduction in myogenin mRNA (Fig. 5B)
and protein (Fig. 5C) levels was observed in C2C12 cells treated
with compound C. The MHC level was also decreased following
compound C treatment (Fig. 5C).
The same treatment regimens were applied to primary myoblasts. AICAR treatment resulted in increased myogenin mRNA
and protein levels, while compound C treatment resulted in reduced myogenin mRNA and protein levels in WT, AMPK␣1 KO,
and AMPK␣2 KO differentiating myoblasts (Fig. 5E and G to I).
Immunofluorescence analysis showed corresponding changes in
myotube formation (Fig. 5F [only images of AMPK␣2 KO cells are
shown]). AICAR treatment increased the MHC protein levels in
WT, AMPK␣1 KO, and AMPK␣2 KO differentiating myoblasts.
Compound C treatment resulted in decreased MHC levels in WT
differentiating myoblasts (Fig. 5G) and AMPK␣2 KO differentiating myoblasts (Fig. 5I) but resulted in an increase in MHC levels
in AMPK␣1 KO differentiating myoblasts (Fig. 5H). Although
further analysis will be necessary, the increased MHC level in
AMPK␣1 KO differentiating myoblasts (AMPK␣2 remaining)
following compound C treatment may be related to the importance of the AMPK␣2 subunit in governing protein synthesis, including MHC synthesis.
AMPK␣1 potentiates myogenic differentiation of engrafted
myoblasts. To test the influence of AMPK KO on myogenic differentiation in vivo, myoblasts were isolated from EGFP WT mice
and DsRed mice with an AMPK␣1 conditional KO. DsRed-expressing AMPK␣1 conditional KO myoblasts were treated with
tamoxifen for 48 h to delete AMPK␣1. CTX was injected into TA
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FIG 3 Double-knockout AMPK␣ subunits dramatically reduce myogenesis. WT and AMPK␣1 and AMPK␣2 double-KO (DK) primary myoblasts were
prepared, purified, and induced for myogenesis. (A) AMPK␣ subunit contents in AMPK␣ DK myoblasts following 4-hydroxytamoxifen (TM) treatment. (B)
Myogenin mRNA expression in AMPK␣ DK myoblasts following TM treatment (2 days after induction of myogenesis). (C) Myogenin and MHC protein
contents in AMPK␣ DK myoblasts following TM treatment (3 days and 4 days after induction of myogenesis, respectively). (D) Immunocytochemical staining
using an anti-MHC antibody and fusion index 4 days after induction of myogenesis following TM treatment. Data shown are means ⫾ SEM (n ⱖ 3). ␣1,
AMPK␣1; ␣2, AMPK␣2. ⴱⴱ, P ⬍ 0.01 versus the WT; ⴱⴱⴱ, P ⬍ 0.0001 versus the WT.

FIG 4 AMPK␣ content in C2C12 cells, primary myoblasts, and skeletal muscle. (A) AMPK␣1 and AMPK␣2 mRNA contents were analyzed 1 day (1D) and 6 days
(6D) after myogenic induction (MG) in C2C12 cells. (B) AMPK␣1 and AMPK␣2 mRNA contents in primary myoblasts before (0D) and 2 days after (2D)
myogenic induction. (C) AMPK␣1 and AMPK␣2 mRNA contents in hind-limb muscle from 2-day-old neonatal (2D) and 2-month-old adult (2M) WT mice.
(D) AMPK␣ and p-AMPK␣ levels in WT, AMPK␣1 KO, and AMPK␣2 KO myoblasts 3 days after myogenic induction. (E) AMPK␣ and p-AMPK␣ levels in
hind-limb muscle from 2-day-old WT, AMPK␣1 KO, and AMPK␣2 KO mice. (F) AMPK␣ and p-AMPK␣ levels in hind-limb muscle from 2-month-old WT,
AMPK␣1 KO, and AMPK␣2 KO mice. (G) AMPK␣1 and AMPK␣2 mRNA levels in undamaged TA muscle and in TA muscle 1 day, 2 days, 3 days, and 4 days
post-cardiotoxin injection (PI). (H) Immunohistochemistry staining of TA muscle sections at 2 days and 3 days post-cardiotoxin injection using anti-EMH
antibody and antilaminin antibody. Data shown are means ⫾ SEM (n ⱖ 3). ␣1, AMPK␣1; ␣2, AMPK␣2. ⴱ, P ⬍ 0.05; ⴱⴱ, P ⬍ 0.01 versus the WT; ⴱⴱⴱ, P ⬍ 0.0001.

muscle of WT mice to induce muscle regeneration. Twenty-four
hours after CTX injection, 3 ⫻ 104 EGFP myoblasts and 3 ⫻ 104
DsRed AMPK␣1 KO myoblasts were mixed and injected together
into each damaged TA muscle. Cotransplantation of WT EGFP
myoblasts and AMPK␣1 KO DsRed myoblasts eliminated the
variations due to the transplantation procedure and physiological
conditions. Fourteen days after myoblast transplantation, a number of EGFP-positive (EGFP⫹) muscle fibers was observed in
transplanted TA muscle, whereas a much smaller number of
DsRed⫹ muscle fibers was observed (Fig. 6). These data clearly
indicate that WT myoblasts had a greater potential to differentiate
into muscle fibers in vivo than AMPK␣1 KO myoblasts, showing
the promoting effect of AMPK␣1 on myogenic differentiation.
DISCUSSION

To date, the relationship between AMPK and myogenesis has been
controversial. A previous study suggested that AMPK activation
blocked myogenesis through a PGC-1␣-dependent mechanism
involving SIRT1 in C2C12 cells (34). However, a high dose of
AICAR (1 mM) was used in this study. Because AMPK is known to
inhibit protein synthesis, highly activated AMPK would be ex-
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pected to inhibit protein synthesis globally and would likely inhibit cell proliferation. Moreover, pathophysiological changes
such as obesity and chronic inflammation are known to inhibit,
rather than activate, AMPK (31), suggesting that inhibition, rather
than activation, is more relevant to the pathophysiological roles of
AMPK (35–37). AMPK is phosphorylated by a constitutively active kinase, LKB1, which suggests that dephosphorylation rather
than phosphorylation may be the main mechanism in the regulation of AMPK activity (37–39). In our previous studies, we observed that low AMPK activity correlated with impaired myogenesis (19). Moreover, we recently reported that AMPK positively
regulates myogenesis through phosphorylation of HDAC5 and
that AMPK␣1 KO but not AMPK␣2 KO was associated with reduced muscle mass (22).
To dissect the relationship between decreased AMPK activity
and myogenesis, we used shRNA to selectively knock down either
AMPK␣1 or AMPK␣2. Our results indicated that AMPK␣1 but not
AMPK␣2 knockdown was associated with decreased myogenesis, as
shown by decreased expression levels of myogenin and MHC and less
formation of myotubes. Our data were further strengthened by using
primary myoblasts isolated from neonatal WT, AMPK␣1 KO, and
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FIG 5 Myogenin levels and myogenesis are associated with AMPK activity in C2C12 cells and primary myoblasts. (A to D) C2C12 cells were induced for
myogenesis in myogenic differentiation medium. The medium was supplemented with either 0.125 mM AICAR or 1 M compound C. Control cultures received
vehicle (dimethyl sulfoxide). (A) Immunoblot of the indicated proteins or phosphoproteins performed 2 days after myogenic induction. (B) Real-time PCR
testing of myogenin mRNA content (2 days after induction of myogenesis). (C) Immunoblot of myogenin and myosin heavy chain (MHC) (3 days and 6 days
after induction of myogenesis, respectively). (D) Immunocytochemical staining for MHC 6 days after induction of myogenesis. (E to I) Primary myoblasts were
induced for myogenesis in myogenic differentiation medium, which was supplemented with either 0.125 mM AICAR, 1 M compound C, or vehicle (dimethyl
sulfoxide). (E) Myogenin mRNA content assessed in WT, AMPK␣1 KO, and AMPK␣2 KO primary myoblasts 2 days after induction of myogenesis. (F)
Immunocytochemical staining for MHC 4 days after induction of myogenesis. (G to I) Myogenin protein content and MHC protein content of myoblasts
assessed by immunoblotting (3 days and 4 days after induction of myogenesis, respectively). (G) WT; (H) AMPK␣1 KO; (I) AMPK␣2 KO. Data shown are
means ⫾ SEM (n ⱖ 3). ␣1, AMPK␣1; ␣2, AMPK␣2. ⴱ, P ⬍ 0.05 versus the control; ⴱⴱ, P ⬍ 0.01 versus the control; ⴱⴱⴱ, P ⬍ 0.0001 versus the control.

AMPK␣2 KO mice. During myogenic differentiation, AMPK␣1 KO
myoblasts showed reduced expression levels of myogenin and MHC
and less formation of myotubes than WT myoblasts. Also, the absence of both AMPK␣1 and AMPK␣2 was associated with further

reductions in myogenesis, which indicates that AMPK activity is necessary for optimal myogenic differentiation.
We questioned why AMPK␣2 depletion failed to reduce myogenin and MHC levels. We postulated that it may be caused, in

FIG 6 AMPK␣1 is critical for myogenic differentiation of engrafted myoblasts. (A to E) Immunostaining of muscle fibers formed by transplanted WT EGFP
myoblasts and DsRed AMPK␣1 KO myoblasts. (E=) Magnified image of a selected area in panel E. (F) Numbers of muscle fibers formed by transplanted
myoblasts in three independent experiments. BF, bright field.
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part, by the differential expression of AMPK␣1 and AMPK␣2 in
myoblasts. Indeed, AMPK␣1 is expressed during the early stages
of myogenesis; however, the AMPK␣2 level increases during myogenic differentiation and becomes the dominant isoform in mature muscle, as indicated by previous reports showing that
AMPK␣2 is the major form in skeletal muscle (40, 41). When
treated with low levels of AICAR, WT, AMPK␣1 KO, and
AMPK␣2 KO myoblasts all showed increased myogenesis, which
indicates that both AMPK␣1 and AMPK␣2 promote myogenesis.
As the dominant AMPK isoform in early differentiating myoblasts, it was not unexpected that AMPK␣1 KO inhibited myogenin expression and myogenesis, while the depletion of AMPK␣2
did not affect myogenesis. This notion is further supported by the
profound upregulation of AMPK␣1 but not AMPK␣2 mRNA expression during muscle regeneration, indicating an important
role of AMPK␣1 in muscle regeneration.
Finally, consistent with our in vitro data, AMPK␣1 KO dramatically reduced myogenic differentiation of myoblasts transplanted
into mouse TA muscle in vivo. Surprisingly, very few or no
AMPK␣1 KO myoblasts fused with muscle fibers, while WT myoblasts did. These data show that AMPK␣1 KO significantly impaired the ability of myoblasts to participate in muscular regeneration, indicating that AMPK␣1 has a critical role in muscle fiber
regeneration. Considering that proper muscle fiber regeneration
is essential for maintaining muscle function (8), improper muscular regeneration due to attenuated AMPK activity is expected to
accelerate muscle atrophy and aging (11).
Our observation that AMPK activity is necessary to maintain
normal myogenesis has important physiological implications, because improper muscle regeneration is largely responsible for
muscle atrophy and loss of contractile function during aging and
muscular atrophy (42). AMPK likely provides a convenient molecular target to facilitate muscle development and muscle regeneration.
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